Our comprehensive analysis delves into the major cross-border deals, including headline-making alliances such as the $12bn GSK-Hengrui partnership, and the rise of South Korea and India as innovation hubs. Whether you’re seeking to understand the impact of shifting US policies on Indian generics, track Japan’s private equity activity, or pinpoint where financial capital is catalysing pharma transformation, Scrip Asia 100 is your gateway to actionable intelligence.
